Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells

BACKGROUND: Human multipotent mesenchymal stromal cells (MSCs) are promising candidates for a growing spectrum of regenerative and immunomodulatory cellular therapies. Translation of auspicious experimental results into clinical applications has been limited by the dependence of MSC propagation from fetal bovine serum (FBS).

[1]  R. Walker,et al.  Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. , 1997, Blood.

[2]  N. Boiret-Dupré,et al.  Cell Culture Medium Composition and Translational Adult Bone Marrow‐Derived Stem Cell Research , 2006, Stem cells.

[3]  R. Marx,et al.  Platelet-rich plasma: Growth factor enhancement for bone grafts. , 1998, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[4]  N. Kulagina,et al.  Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. , 1974, Experimental Hematology.

[5]  Dirk Strunk,et al.  Two steps to functional mesenchymal stromal cells for clinical application , 2007, Transfusion.

[6]  Paquita Nurden,et al.  Autologous platelets as a source of proteins for healing and tissue regeneration , 2003, Thrombosis and Haemostasis.

[7]  P. Nurden,et al.  New insights into and novel applications for platelet-rich fibrin therapies. , 2006, Trends in biotechnology.

[8]  M. Jansson,et al.  Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta , 2005, Transplantation.

[9]  S. Ivanovski,et al.  The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. , 2006, Clinical oral implants research.

[10]  R. Handgretinger,et al.  Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. , 2006, Cytotherapy.

[11]  D. Bonnet,et al.  In Vivo Formation of Unstable Heterokaryons after Liver Damage and Hematopoietic Stem Cell/Progenitor Transplantation , 2006, Stem cells.

[12]  P. Watkins,et al.  Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. , 1999, Experimental hematology.

[13]  C. Dunbar,et al.  Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. , 2003, Blood.

[14]  J. Wiltfang,et al.  Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates , 2003, Vox sanguinis.

[15]  D. Hom,et al.  The effects of tissue sealants, platelet gels, and growth factors on wound healing , 2003, Current opinion in otolaryngology & head and neck surgery.

[16]  A. Friedenstein,et al.  Factors required for bone marrow stromal fibroblast colony formation in vitro , 1997, British journal of haematology.

[17]  I. Martineau,et al.  Platelet-rich Plasmas: Growth Factor Content and Roles in Wound Healing , 2005, Journal of dental research.

[18]  Shu-Ching Hsu,et al.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  F. Frommlet,et al.  Platelets are mitogenic for periosteum‐derived cells , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[20]  O. Kilian,et al.  Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. , 2004, European journal of medical research.

[21]  S. Perez,et al.  Cell Culture Medium Composition and Translational Adult Bone Marrow‐Derived Stem Cell Research , 2006, Stem cells.

[22]  A. Aguzzi,et al.  Medicinal and other products and human and animal transmissible spongiform encephalopathies: memorandum from a WHO meeting. , 1997, Bulletin of the World Health Organization.

[23]  Jeffrey L. Spees,et al.  Enhanced Engraftment of Mesenchymal Stem Cells in a Cutaneous Wound Model by Culture in Allogenic Species‐Specific Serum and Administration in Fibrin Constructs , 2006, Stem cells.

[24]  N. Baldini,et al.  In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet‐rich plasma, and freeze‐dried bone allografts, alone and in combination , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[25]  S. Gronthos,et al.  The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro. , 1995, Blood.

[26]  J. Wiltfang,et al.  Different preparation methods to obtain platelet components as a source of growth factors for local application , 2001, Transfusion.

[27]  F. Djouad,et al.  Engineered mesenchymal stem cells for cartilage repair. , 2006, Regenerative medicine.

[28]  A I Caplan,et al.  Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. , 1995, Bone marrow transplantation.

[29]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[30]  Luca Sangiorgi,et al.  Platelet-derived growth factors enhance proliferation of human stromal stem cells. , 2003, Biomaterials.

[31]  P. Moy,et al.  Investigation of platelet-rich plasma in rabbit cranial defects: A pilot study. , 2002, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[32]  A. Mackensen,et al.  Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells , 2000, Cancer Immunology, Immunotherapy.

[33]  G. Watzek,et al.  Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. , 2002, Clinical oral implants research.

[34]  P. Claudio,et al.  Use of autologous platelet-rich plasma (PRP) in periodontal defect treatment after extraction of impacted mandibular third molars. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[35]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[36]  Andrea Bacigalupo,et al.  Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  X. Holy,et al.  Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications , 2005, Journal of cellular physiology.

[38]  Myoung-Woo Lee,et al.  Mesenchymal stem cells from cryopreserved human umbilical cord blood. , 2004, Biochemical and biophysical research communications.

[39]  S. Gerson,et al.  Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Strunk,et al.  Phenotypic characterization and preclinical production of human lineage‐negative cells for regenerative stem cell therapy , 2005, Transfusion.

[42]  J. Gimble,et al.  The Derivation and Characterization of Stromal Cell Lines from the Bone Marrow of p53−/− Mice: New Insights into Osteoblast and Adipocyte Differentiation , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  L. Muul,et al.  Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. , 2002, Human gene therapy.

[44]  A. Vissink,et al.  Does platelet-rich plasma promote remodeling of autologous bone grafts used for augmentation of the maxillary sinus floor? , 2005, Clinical oral implants research.

[45]  A. V. van Zundert,et al.  Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation , 2006, Transfusion medicine.

[46]  J. Cheong,et al.  Treatment of high‐risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co‐infusion of T cell‐depleted haematopoietic stem cells and culture‐expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype , 2002, British journal of haematology.

[47]  A. Meunier,et al.  Effects of platelet lysates on select bone cell functions. , 2004, Clinical oral implants research.

[48]  L. Mazzucco,et al.  Tissue regeneration and in loco administration of platelet derivatives: clinical outcome, heterogeneous products, and heterogeneity of the effector mechanisms , 2005, Transfusion.

[49]  S. Gerson,et al.  Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH) , 2002, Bone Marrow Transplantation.

[50]  정준원,et al.  Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype , 2002 .

[51]  L. Sangiorgi,et al.  Stromal Stem Cells and Platelet-Rich Plasma Improve Bone Allograft Integration , 2005, Clinical orthopaedics and related research.